Amyris to Acquire Oobli, Adding Precision-Fermented Sweet Proteins Brazzein, Monellin and Thaumatin to Its Biomanufacturing Platform
Biomanufacturer Amyris has agreed to acquire sweet protein developer Oobli for an undisclosed sum, pairing its strain engineering with Oobli’s FDA GRAS brazzein and monellin and its thaumatin pipeline. Amyris says it will keep Oobli’s contract manufacturers, pricing…



















